Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Edwards Lifesciences Corp. debt to equity ratio improved from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Debt to equity (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Edwards Lifesciences Corp. debt to equity ratio (including operating lease liability) improved from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Edwards Lifesciences Corp. debt to capital ratio improved from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Debt to capital (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Edwards Lifesciences Corp. debt to capital ratio (including operating lease liability) improved from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Edwards Lifesciences Corp. debt to assets ratio improved from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Debt to assets (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Edwards Lifesciences Corp. debt to assets ratio (including operating lease liability) improved from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Edwards Lifesciences Corp. financial leverage ratio decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Debt to Equity
Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
Short-term debt | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 599,900) | 599,200) | 598,600) | 598,000) | —) | —) | —) | ||||||
Long-term debt | 595,700) | 595,500) | 595,400) | 595,200) | 595,000) | 594,900) | 594,700) | 594,600) | 594,400) | 594,200) | 594,100) | 593,900) | 593,800) | 593,600) | 593,900) | 456,000) | 438,400) | 1,034,000) | 1,016,800) | 847,900) | ||||||
Total debt | 595,700) | 595,500) | 595,400) | 595,200) | 595,000) | 594,900) | 594,700) | 594,600) | 594,400) | 594,200) | 594,100) | 593,900) | 593,800) | 1,193,500) | 1,193,100) | 1,054,600) | 1,036,400) | 1,034,000) | 1,016,800) | 847,900) | ||||||
Stockholders’ equity | 5,835,900) | 5,541,300) | 5,133,300) | 4,658,400) | 4,574,300) | 4,210,300) | 3,839,100) | 3,901,100) | 4,148,300) | 3,814,800) | 3,500,300) | 3,447,500) | 3,140,400) | 3,361,300) | 3,164,200) | 3,245,700) | 2,956,200) | 3,162,500) | 2,939,600) | 2,742,700) | ||||||
Solvency Ratio | ||||||||||||||||||||||||||
Debt to equity1 | 0.10 | 0.11 | 0.12 | 0.13 | 0.13 | 0.14 | 0.15 | 0.15 | 0.14 | 0.16 | 0.17 | 0.17 | 0.19 | 0.36 | 0.38 | 0.32 | 0.35 | 0.33 | 0.35 | 0.31 | ||||||
Benchmarks | ||||||||||||||||||||||||||
Debt to Equity, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | 0.50 | 0.53 | 0.55 | 0.55 | 0.57 | 0.59 | 0.64 | 0.60 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Cigna Group | 0.71 | 0.72 | 0.68 | 0.66 | 0.65 | 0.75 | 0.77 | 0.81 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
CVS Health Corp. | 0.75 | 0.79 | 0.81 | 0.87 | 0.93 | 0.97 | 1.05 | 1.10 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Elevance Health Inc. | 0.64 | 0.64 | 0.66 | 0.69 | 0.60 | 0.61 | 0.62 | 0.68 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Medtronic PLC | 0.51 | 0.60 | 0.60 | 0.57 | 0.49 | 0.49 | 0.51 | 0.52 | 0.51 | 0.50 | 0.50 | 0.50 | — | — | — | — | — | — | — | — | ||||||
UnitedHealth Group Inc. | 0.64 | 0.67 | 0.70 | 0.70 | 0.66 | 0.67 | 0.72 | 0.91 | — | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q4 2021 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity
= 595,700 ÷ 5,835,900 = 0.10
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Edwards Lifesciences Corp. debt to equity ratio improved from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Debt to Equity (including Operating Lease Liability)
Edwards Lifesciences Corp., debt to equity (including operating lease liability) calculation (quarterly data)
Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
Short-term debt | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 599,900) | 599,200) | 598,600) | 598,000) | —) | —) | —) | ||||||
Long-term debt | 595,700) | 595,500) | 595,400) | 595,200) | 595,000) | 594,900) | 594,700) | 594,600) | 594,400) | 594,200) | 594,100) | 593,900) | 593,800) | 593,600) | 593,900) | 456,000) | 438,400) | 1,034,000) | 1,016,800) | 847,900) | ||||||
Total debt | 595,700) | 595,500) | 595,400) | 595,200) | 595,000) | 594,900) | 594,700) | 594,600) | 594,400) | 594,200) | 594,100) | 593,900) | 593,800) | 1,193,500) | 1,193,100) | 1,054,600) | 1,036,400) | 1,034,000) | 1,016,800) | 847,900) | ||||||
Operating lease liabilities, current portion | 25,500) | 24,200) | 25,100) | 26,500) | 27,200) | 24,200) | 23,800) | 24,900) | 25,500) | 24,100) | 23,800) | 22,600) | —) | —) | —) | —) | —) | —) | —) | —) | ||||||
Operating lease liabilities, long-term portion | 69,100) | 64,400) | 63,700) | 67,100) | 72,700) | 71,000) | 66,000) | 55,700) | 58,900) | 52,400) | 50,400) | 49,700) | —) | —) | —) | —) | —) | —) | —) | —) | ||||||
Total debt (including operating lease liability) | 690,300) | 684,100) | 684,200) | 688,800) | 694,900) | 690,100) | 684,500) | 675,200) | 678,800) | 670,700) | 668,300) | 666,200) | 593,800) | 1,193,500) | 1,193,100) | 1,054,600) | 1,036,400) | 1,034,000) | 1,016,800) | 847,900) | ||||||
Stockholders’ equity | 5,835,900) | 5,541,300) | 5,133,300) | 4,658,400) | 4,574,300) | 4,210,300) | 3,839,100) | 3,901,100) | 4,148,300) | 3,814,800) | 3,500,300) | 3,447,500) | 3,140,400) | 3,361,300) | 3,164,200) | 3,245,700) | 2,956,200) | 3,162,500) | 2,939,600) | 2,742,700) | ||||||
Solvency Ratio | ||||||||||||||||||||||||||
Debt to equity (including operating lease liability)1 | 0.12 | 0.12 | 0.13 | 0.15 | 0.15 | 0.16 | 0.18 | 0.17 | 0.16 | 0.18 | 0.19 | 0.19 | 0.19 | 0.36 | 0.38 | 0.32 | 0.35 | 0.33 | 0.35 | 0.31 | ||||||
Benchmarks | ||||||||||||||||||||||||||
Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||||||||||||||||||||||
CVS Health Corp. | 1.01 | 1.06 | 1.09 | 1.16 | 1.23 | 1.27 | 1.35 | 1.42 | — | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q4 2021 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Stockholders’ equity
= 690,300 ÷ 5,835,900 = 0.12
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to equity (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Edwards Lifesciences Corp. debt to equity ratio (including operating lease liability) improved from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Debt to Capital
Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
Short-term debt | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 599,900) | 599,200) | 598,600) | 598,000) | —) | —) | —) | ||||||
Long-term debt | 595,700) | 595,500) | 595,400) | 595,200) | 595,000) | 594,900) | 594,700) | 594,600) | 594,400) | 594,200) | 594,100) | 593,900) | 593,800) | 593,600) | 593,900) | 456,000) | 438,400) | 1,034,000) | 1,016,800) | 847,900) | ||||||
Total debt | 595,700) | 595,500) | 595,400) | 595,200) | 595,000) | 594,900) | 594,700) | 594,600) | 594,400) | 594,200) | 594,100) | 593,900) | 593,800) | 1,193,500) | 1,193,100) | 1,054,600) | 1,036,400) | 1,034,000) | 1,016,800) | 847,900) | ||||||
Stockholders’ equity | 5,835,900) | 5,541,300) | 5,133,300) | 4,658,400) | 4,574,300) | 4,210,300) | 3,839,100) | 3,901,100) | 4,148,300) | 3,814,800) | 3,500,300) | 3,447,500) | 3,140,400) | 3,361,300) | 3,164,200) | 3,245,700) | 2,956,200) | 3,162,500) | 2,939,600) | 2,742,700) | ||||||
Total capital | 6,431,600) | 6,136,800) | 5,728,700) | 5,253,600) | 5,169,300) | 4,805,200) | 4,433,800) | 4,495,700) | 4,742,700) | 4,409,000) | 4,094,400) | 4,041,400) | 3,734,200) | 4,554,800) | 4,357,300) | 4,300,300) | 3,992,600) | 4,196,500) | 3,956,400) | 3,590,600) | ||||||
Solvency Ratio | ||||||||||||||||||||||||||
Debt to capital1 | 0.09 | 0.10 | 0.10 | 0.11 | 0.12 | 0.12 | 0.13 | 0.13 | 0.13 | 0.13 | 0.15 | 0.15 | 0.16 | 0.26 | 0.27 | 0.25 | 0.26 | 0.25 | 0.26 | 0.24 | ||||||
Benchmarks | ||||||||||||||||||||||||||
Debt to Capital, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | 0.34 | 0.35 | 0.35 | 0.35 | 0.36 | 0.37 | 0.39 | 0.38 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Cigna Group | 0.42 | 0.42 | 0.40 | 0.40 | 0.40 | 0.43 | 0.44 | 0.45 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
CVS Health Corp. | 0.43 | 0.44 | 0.45 | 0.47 | 0.48 | 0.49 | 0.51 | 0.52 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Elevance Health Inc. | 0.39 | 0.39 | 0.40 | 0.41 | 0.38 | 0.38 | 0.38 | 0.41 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Medtronic PLC | 0.34 | 0.37 | 0.37 | 0.36 | 0.33 | 0.33 | 0.34 | 0.34 | 0.34 | 0.33 | 0.34 | 0.33 | — | — | — | — | — | — | — | — | ||||||
UnitedHealth Group Inc. | 0.39 | 0.40 | 0.41 | 0.41 | 0.40 | 0.40 | 0.42 | 0.48 | — | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q4 2021 Calculation
Debt to capital = Total debt ÷ Total capital
= 595,700 ÷ 6,431,600 = 0.09
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Edwards Lifesciences Corp. debt to capital ratio improved from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Debt to Capital (including Operating Lease Liability)
Edwards Lifesciences Corp., debt to capital (including operating lease liability) calculation (quarterly data)
Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
Short-term debt | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 599,900) | 599,200) | 598,600) | 598,000) | —) | —) | —) | ||||||
Long-term debt | 595,700) | 595,500) | 595,400) | 595,200) | 595,000) | 594,900) | 594,700) | 594,600) | 594,400) | 594,200) | 594,100) | 593,900) | 593,800) | 593,600) | 593,900) | 456,000) | 438,400) | 1,034,000) | 1,016,800) | 847,900) | ||||||
Total debt | 595,700) | 595,500) | 595,400) | 595,200) | 595,000) | 594,900) | 594,700) | 594,600) | 594,400) | 594,200) | 594,100) | 593,900) | 593,800) | 1,193,500) | 1,193,100) | 1,054,600) | 1,036,400) | 1,034,000) | 1,016,800) | 847,900) | ||||||
Operating lease liabilities, current portion | 25,500) | 24,200) | 25,100) | 26,500) | 27,200) | 24,200) | 23,800) | 24,900) | 25,500) | 24,100) | 23,800) | 22,600) | —) | —) | —) | —) | —) | —) | —) | —) | ||||||
Operating lease liabilities, long-term portion | 69,100) | 64,400) | 63,700) | 67,100) | 72,700) | 71,000) | 66,000) | 55,700) | 58,900) | 52,400) | 50,400) | 49,700) | —) | —) | —) | —) | —) | —) | —) | —) | ||||||
Total debt (including operating lease liability) | 690,300) | 684,100) | 684,200) | 688,800) | 694,900) | 690,100) | 684,500) | 675,200) | 678,800) | 670,700) | 668,300) | 666,200) | 593,800) | 1,193,500) | 1,193,100) | 1,054,600) | 1,036,400) | 1,034,000) | 1,016,800) | 847,900) | ||||||
Stockholders’ equity | 5,835,900) | 5,541,300) | 5,133,300) | 4,658,400) | 4,574,300) | 4,210,300) | 3,839,100) | 3,901,100) | 4,148,300) | 3,814,800) | 3,500,300) | 3,447,500) | 3,140,400) | 3,361,300) | 3,164,200) | 3,245,700) | 2,956,200) | 3,162,500) | 2,939,600) | 2,742,700) | ||||||
Total capital (including operating lease liability) | 6,526,200) | 6,225,400) | 5,817,500) | 5,347,200) | 5,269,200) | 4,900,400) | 4,523,600) | 4,576,300) | 4,827,100) | 4,485,500) | 4,168,600) | 4,113,700) | 3,734,200) | 4,554,800) | 4,357,300) | 4,300,300) | 3,992,600) | 4,196,500) | 3,956,400) | 3,590,600) | ||||||
Solvency Ratio | ||||||||||||||||||||||||||
Debt to capital (including operating lease liability)1 | 0.11 | 0.11 | 0.12 | 0.13 | 0.13 | 0.14 | 0.15 | 0.15 | 0.14 | 0.15 | 0.16 | 0.16 | 0.16 | 0.26 | 0.27 | 0.25 | 0.26 | 0.25 | 0.26 | 0.24 | ||||||
Benchmarks | ||||||||||||||||||||||||||
Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||||||||||||||||||||||
CVS Health Corp. | 0.50 | 0.51 | 0.52 | 0.54 | 0.55 | 0.56 | 0.58 | 0.59 | — | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q4 2021 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= 690,300 ÷ 6,526,200 = 0.11
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to capital (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Edwards Lifesciences Corp. debt to capital ratio (including operating lease liability) improved from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Debt to Assets
Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
Short-term debt | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 599,900) | 599,200) | 598,600) | 598,000) | —) | —) | —) | ||||||
Long-term debt | 595,700) | 595,500) | 595,400) | 595,200) | 595,000) | 594,900) | 594,700) | 594,600) | 594,400) | 594,200) | 594,100) | 593,900) | 593,800) | 593,600) | 593,900) | 456,000) | 438,400) | 1,034,000) | 1,016,800) | 847,900) | ||||||
Total debt | 595,700) | 595,500) | 595,400) | 595,200) | 595,000) | 594,900) | 594,700) | 594,600) | 594,400) | 594,200) | 594,100) | 593,900) | 593,800) | 1,193,500) | 1,193,100) | 1,054,600) | 1,036,400) | 1,034,000) | 1,016,800) | 847,900) | ||||||
Total assets | 8,502,600) | 8,160,300) | 7,662,100) | 7,213,700) | 7,237,100) | 6,800,800) | 6,424,100) | 6,076,100) | 6,488,100) | 5,966,300) | 5,573,500) | 5,469,300) | 5,323,700) | 5,958,200) | 5,686,100) | 5,825,100) | 5,695,800) | 5,488,400) | 5,138,500) | 4,780,400) | ||||||
Solvency Ratio | ||||||||||||||||||||||||||
Debt to assets1 | 0.07 | 0.07 | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 | 0.10 | 0.09 | 0.10 | 0.11 | 0.11 | 0.11 | 0.20 | 0.21 | 0.18 | 0.18 | 0.19 | 0.20 | 0.18 | ||||||
Benchmarks | ||||||||||||||||||||||||||
Debt to Assets, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | 0.24 | 0.25 | 0.25 | 0.25 | 0.26 | 0.27 | 0.29 | 0.27 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Cigna Group | 0.22 | 0.22 | 0.21 | 0.21 | 0.21 | 0.22 | 0.23 | 0.24 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
CVS Health Corp. | 0.24 | 0.25 | 0.26 | 0.27 | 0.28 | 0.29 | 0.30 | 0.31 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Elevance Health Inc. | 0.24 | 0.23 | 0.24 | 0.24 | 0.23 | 0.24 | 0.24 | 0.26 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Medtronic PLC | 0.28 | 0.31 | 0.31 | 0.31 | 0.27 | 0.28 | 0.28 | 0.29 | 0.28 | 0.28 | 0.28 | 0.28 | — | — | — | — | — | — | — | — | ||||||
UnitedHealth Group Inc. | 0.22 | 0.22 | 0.23 | 0.23 | 0.22 | 0.23 | 0.24 | 0.27 | — | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q4 2021 Calculation
Debt to assets = Total debt ÷ Total assets
= 595,700 ÷ 8,502,600 = 0.07
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Edwards Lifesciences Corp. debt to assets ratio improved from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Debt to Assets (including Operating Lease Liability)
Edwards Lifesciences Corp., debt to assets (including operating lease liability) calculation (quarterly data)
Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
Short-term debt | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 599,900) | 599,200) | 598,600) | 598,000) | —) | —) | —) | ||||||
Long-term debt | 595,700) | 595,500) | 595,400) | 595,200) | 595,000) | 594,900) | 594,700) | 594,600) | 594,400) | 594,200) | 594,100) | 593,900) | 593,800) | 593,600) | 593,900) | 456,000) | 438,400) | 1,034,000) | 1,016,800) | 847,900) | ||||||
Total debt | 595,700) | 595,500) | 595,400) | 595,200) | 595,000) | 594,900) | 594,700) | 594,600) | 594,400) | 594,200) | 594,100) | 593,900) | 593,800) | 1,193,500) | 1,193,100) | 1,054,600) | 1,036,400) | 1,034,000) | 1,016,800) | 847,900) | ||||||
Operating lease liabilities, current portion | 25,500) | 24,200) | 25,100) | 26,500) | 27,200) | 24,200) | 23,800) | 24,900) | 25,500) | 24,100) | 23,800) | 22,600) | —) | —) | —) | —) | —) | —) | —) | —) | ||||||
Operating lease liabilities, long-term portion | 69,100) | 64,400) | 63,700) | 67,100) | 72,700) | 71,000) | 66,000) | 55,700) | 58,900) | 52,400) | 50,400) | 49,700) | —) | —) | —) | —) | —) | —) | —) | —) | ||||||
Total debt (including operating lease liability) | 690,300) | 684,100) | 684,200) | 688,800) | 694,900) | 690,100) | 684,500) | 675,200) | 678,800) | 670,700) | 668,300) | 666,200) | 593,800) | 1,193,500) | 1,193,100) | 1,054,600) | 1,036,400) | 1,034,000) | 1,016,800) | 847,900) | ||||||
Total assets | 8,502,600) | 8,160,300) | 7,662,100) | 7,213,700) | 7,237,100) | 6,800,800) | 6,424,100) | 6,076,100) | 6,488,100) | 5,966,300) | 5,573,500) | 5,469,300) | 5,323,700) | 5,958,200) | 5,686,100) | 5,825,100) | 5,695,800) | 5,488,400) | 5,138,500) | 4,780,400) | ||||||
Solvency Ratio | ||||||||||||||||||||||||||
Debt to assets (including operating lease liability)1 | 0.08 | 0.08 | 0.09 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.10 | 0.11 | 0.12 | 0.12 | 0.11 | 0.20 | 0.21 | 0.18 | 0.18 | 0.19 | 0.20 | 0.18 | ||||||
Benchmarks | ||||||||||||||||||||||||||
Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||||||||||||||||||||||
CVS Health Corp. | 0.33 | 0.33 | 0.34 | 0.36 | 0.37 | 0.37 | 0.39 | 0.40 | — | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q4 2021 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= 690,300 ÷ 8,502,600 = 0.08
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to assets (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Edwards Lifesciences Corp. debt to assets ratio (including operating lease liability) improved from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Financial Leverage
Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
Total assets | 8,502,600) | 8,160,300) | 7,662,100) | 7,213,700) | 7,237,100) | 6,800,800) | 6,424,100) | 6,076,100) | 6,488,100) | 5,966,300) | 5,573,500) | 5,469,300) | 5,323,700) | 5,958,200) | 5,686,100) | 5,825,100) | 5,695,800) | 5,488,400) | 5,138,500) | 4,780,400) | ||||||
Stockholders’ equity | 5,835,900) | 5,541,300) | 5,133,300) | 4,658,400) | 4,574,300) | 4,210,300) | 3,839,100) | 3,901,100) | 4,148,300) | 3,814,800) | 3,500,300) | 3,447,500) | 3,140,400) | 3,361,300) | 3,164,200) | 3,245,700) | 2,956,200) | 3,162,500) | 2,939,600) | 2,742,700) | ||||||
Solvency Ratio | ||||||||||||||||||||||||||
Financial leverage1 | 1.46 | 1.47 | 1.49 | 1.55 | 1.58 | 1.62 | 1.67 | 1.56 | 1.56 | 1.56 | 1.59 | 1.59 | 1.70 | 1.77 | 1.80 | 1.79 | 1.93 | 1.74 | 1.75 | 1.74 | ||||||
Benchmarks | ||||||||||||||||||||||||||
Financial Leverage, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | 2.10 | 2.14 | 2.17 | 2.17 | 2.21 | 2.20 | 2.25 | 2.21 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Cigna Group | 3.29 | 3.25 | 3.17 | 3.16 | 3.09 | 3.33 | 3.37 | 3.43 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
CVS Health Corp. | 3.10 | 3.16 | 3.16 | 3.24 | 3.32 | 3.38 | 3.46 | 3.54 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Elevance Health Inc. | 2.70 | 2.74 | 2.75 | 2.83 | 2.61 | 2.55 | 2.55 | 2.60 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Intuitive Surgical Inc. | 1.14 | 1.13 | 1.13 | 1.14 | 1.15 | 1.15 | 1.16 | 1.16 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Medtronic PLC | 1.81 | 1.92 | 1.91 | 1.87 | 1.79 | 1.79 | 1.80 | 1.81 | 1.79 | 1.78 | 1.78 | 1.79 | — | — | — | — | — | — | — | — | ||||||
UnitedHealth Group Inc. | 2.96 | 3.03 | 3.05 | 3.09 | 3.01 | 2.93 | 3.03 | 3.32 | — | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q4 2021 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity
= 8,502,600 ÷ 5,835,900 = 1.46
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Edwards Lifesciences Corp. financial leverage ratio decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |